Zynerba Zygel transdermales Cannabidiol (CBD) (Seite 6)

eröffnet am 21.06.20 19:52:26 von
neuester Beitrag 07.05.21 22:21:05 von

Beitrag schreiben

Begriffe und/oder Benutzer



 Ja Nein
10.03.21 14:17:02
Die Zahlen sind raus. Wobei es ungeachtet dieser ein spanendes Jahr 2021 für ZYNE zu werden scheint.…
Zynerba Pharmaceuticals | 3,712 €
15.03.21 22:07:49
Ähm, was ist bitte schön gerade mit dem Kurs passiert und warum hat sich einer an der Nasdaq 1,5 Millionen Aktien gekauft

Zynerba Pharmaceuticals | 7,030 $
07.05.21 22:21:05
Zynerba receives FDA guidance for Phase 3 trial design for Zygel in rare genetic disorder

Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced that the FDA has issued guidance for a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome ("FXS"), a rare genetic disorder causing developmental disability.

Named RECONNECT, the randomized, double-blind, and placebo-controlled study will enroll about 200 children and adolescents.

It is expected to start in Q3 2021, and positive results could be adequate to submit a New Drug Application for Zygel in patients with FXS, the company said.

“If the results are positive, Zygel could become the first FDA-approved treatment option for the significant unmet medical need that affects patients with FXS and their families,” commented Armando Anido, CEO of Zynerba.

The 18-week study is designed to confirm the positive results seen in a subset of responders in the company’s CONNECT-FX trial.

Zynerba Pharmaceuticals | 3,702 €

Beitrag zu dieser Diskussion schreiben

Zynerba Zygel transdermales Cannabidiol (CBD)